Citius Pharma raises $5M via registered direct offering and private placement

Citius Pharmaceuticals, Inc.

Sold 5,076,143 shares/pre-funded warrants at $0.985 each; raised ~$5M gross, $4.5M net.
Issued unregistered warrants to purchase 5,076,143 shares at $0.86, 5-year term, cashless exercise.
Net proceeds to fund commercial launch of LYMPHIR and development of product candidates.
45-day lock-up on further equity issuance after closing; H.C. Wainwright acted as placement agent.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Citius Pharmaceuticals, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $5.0 million (effective 2026-04-23).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: approximately $5.0 million
Effective: 2026-04-23

Exact text from the filing

On April 23, 2026, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 4,730,457 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), and pre-funded warrants to purchase up to 345,686 shares of common stock (the “Pre-funded Warrants”) at an offering price of $0.985 and $0.9849, respectively.

View on SEC.gov

Browse all material agreements →

Citius Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-047599

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.